CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer

Pancreatic ductal adenocarcinoma is a highly lethal cancer, and approximately 40% of patients present with non-metastatic locally advanced pancreatic cancer (LAPC) that is not suitable for surgical resection. To improve outcomes in this patient group, local ablative treatments are being explored. Radionuclide therapy (RNT) is a promising option that delivers high-dose internal radiation directly into the tumor, potentially achieving better local tumor control while sparing surrounding tissues compared with external-beam radiation therapy. The OncoSil™ device is a type of RNT containing Phospho

Trial Details

NCT ID
NCT07595835
Phase
PHASE1 / PHASE2
Sponsor
M.R. Meijerink
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • CT-guided percutaneous intratumoural implantation of the OncoSil™ device
Locations (sample)
  • Amsterdam, North Holland, Netherlands|52.37403,4.88969

Key Eligibility Criteria

  • Age ≥18 years
  • Locally advanced pancreatic cancer, defined by the DPCG consensus criteria as: arterial involvement \>90 degrees or venous involvement \>270 degrees.
  • At least RECIST stable disease after a minimum two months of chemotherapy according to current clinical practice\*
  • Capable of providing written and oral informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →